TW202233684A - 結合於葉酸受體α之重鏈抗體 - Google Patents

結合於葉酸受體α之重鏈抗體 Download PDF

Info

Publication number
TW202233684A
TW202233684A TW110142033A TW110142033A TW202233684A TW 202233684 A TW202233684 A TW 202233684A TW 110142033 A TW110142033 A TW 110142033A TW 110142033 A TW110142033 A TW 110142033A TW 202233684 A TW202233684 A TW 202233684A
Authority
TW
Taiwan
Prior art keywords
ser
seq
gly
val
sequence
Prior art date
Application number
TW110142033A
Other languages
English (en)
Chinese (zh)
Inventor
布萊恩 亞凡吉諾
凱瑟琳 哈里斯
哈尼斯 克姆
納森 特倫柯林
Original Assignee
美商泰尼歐生物公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰尼歐生物公司 filed Critical 美商泰尼歐生物公司
Publication of TW202233684A publication Critical patent/TW202233684A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110142033A 2020-11-18 2021-11-11 結合於葉酸受體α之重鏈抗體 TW202233684A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18
US63/115,436 2020-11-18

Publications (1)

Publication Number Publication Date
TW202233684A true TW202233684A (zh) 2022-09-01

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142033A TW202233684A (zh) 2020-11-18 2021-11-11 結合於葉酸受體α之重鏈抗體

Country Status (18)

Country Link
US (1) US20240002498A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247498A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549851A (cg-RX-API-DMAC7.html)
KR (1) KR20230110303A (cg-RX-API-DMAC7.html)
CN (1) CN116615253A (cg-RX-API-DMAC7.html)
AR (1) AR124084A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021383743A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199785A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001432A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006790A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230259A (cg-RX-API-DMAC7.html)
IL (1) IL302670A (cg-RX-API-DMAC7.html)
JO (1) JOP20230109A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005693A (cg-RX-API-DMAC7.html)
PE (1) PE20231203A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233684A (cg-RX-API-DMAC7.html)
UY (1) UY39522A (cg-RX-API-DMAC7.html)
WO (1) WO2022109010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
EP4577576A4 (en) * 2022-08-22 2026-08-12 Abdera Therapeutics Inc KIDNEY-TARGETING ANTIBODIES
TW202608930A (zh) * 2024-06-05 2026-03-01 大陸商長春金賽藥業有限責任公司 靶向葉酸受體α(FRα)的抗體、雙特異性抗體和偶聯物,及其製備和用途
WO2026133379A1 (en) * 2024-12-20 2026-06-25 Fondazione Irccs Istituto Nazionale Dei Tumori Bispecific antibodies directed against alpha-folate receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3765521A4 (en) * 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
CA3133654A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma

Also Published As

Publication number Publication date
US20240002498A1 (en) 2024-01-04
CL2025003126A1 (es) 2026-01-23
EP4247498A1 (en) 2023-09-27
AU2021383743A1 (en) 2023-06-08
IL302670A (en) 2023-07-01
CO2023006790A2 (es) 2023-06-09
CR20230259A (es) 2023-07-13
AU2021383743A9 (en) 2024-09-26
CN116615253A (zh) 2023-08-18
WO2022109010A1 (en) 2022-05-27
UY39522A (es) 2022-06-30
PE20231203A1 (es) 2023-08-17
KR20230110303A (ko) 2023-07-21
CL2023001432A1 (es) 2024-01-05
CA3199785A1 (en) 2022-05-27
MX2023005693A (es) 2023-05-29
AR124084A1 (es) 2023-02-08
JP2023549851A (ja) 2023-11-29
JOP20230109A1 (ar) 2023-05-18

Similar Documents

Publication Publication Date Title
JP7737488B2 (ja) Cd19に結合する重鎖抗体
CA3176792C (en) Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
US20250236681A1 (en) Heavy chain antibodies binding to psma
TWI912972B (zh) 與cd22及cd3結合之多特異性重鏈抗體
US20240002498A1 (en) Heavy chain antibodies binding to folate receptor alpha
JP2026071208A (ja) Bcmaに結合する多重特異性抗体
JP2024507540A (ja) 抗psma抗体及びcar-t構造
KR20230171952A (ko) 항-cd20 항체 및 car-t 구조
RU2824170C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd19
EA053218B1 (ru) Антитела на основе тяжелых цепей, связывающиеся с альфа-рецептором фолата
HK40100966A (en) Heavy chain antibodies binding to cd19
EA050239B1 (ru) Мультиспецифические антитела, связывающиеся с bcma
EA049498B1 (ru) Антитела к cd20 и car-t-клеточные структуры
HK40044275B (en) Heavy chain antibodies binding to cd19
HK40044275A (en) Heavy chain antibodies binding to cd19